Translate Bio researches, develops and commercializes mRNA therapeutics to treat gene dysfunction diseases. Read more

464 Followers on Owler
464 Followers on Owler
464 Followers on Owler
464 Followers on Owler

Translate Bio researches, develops and commercializes mRNA therapeutics to treat gene dysfunction diseases. Read more

Ronald C. Renaud's photo - CEO of Translate Bio

CEO

Ronald C. Renaud

CEO Approval Rating

82/100

Founded:

2016

Status:

PublicIndependent CompanyNASDAQTBIO

TOP COMPETITORS OR ALTERNATIVES

RANK

COMPANY

CEO

CEO RATING

EMPLOYEES

FUNDING

REVENUE

Missing a competitor? Contribute!

NexImmune is seen as one of Translate Bio's top competitors. NexImmune's headquarters is in Gaithersburg, Maryland, and was founded in 2011. Like Translate Bio, NexImmune also works within the Biotechnology industry. NexImmune generates 24% of Translate Bio's revenue.

Checkmate Pharmaceuticals is one of Translate Bio's top rivals. Checkmate Pharmaceuticals was founded in 2015, and its headquarters is in Cambridge, Massachusetts. Like Translate Bio, Checkmate Pharmaceuticals also works within the Biotechnology field. Checkmate Pharmaceuticals has 62 fewer employees than Translate Bio.

Repare Therapeutics Inc. is Translate Bio's #3 rival. Repare Therapeutics Inc. is a Public company that was founded in 2016 in St. Laurent, Quebec. Like Translate Bio, Repare Therapeutics Inc. also competes in the Biotechnology sector. Compared to Translate Bio, Repare Therapeutics Inc. has 17 fewer employees.

Weigh-in!

Help the Owler community know more

Competitor - 1/1

Is Siamab Therapeutics a competitor of Translate Bio?

Quarterly and Annual Revenue

Trailing 12-Months Trend (TTM)

Annual Revenue

$91.3M

Translate Bio's revenue is the ranked 3rd among it's top 10 competitors. The top 10 competitors average 42.6M. Over the last four quarters, Translate Bio's revenue has grown by 1608.1%. Specifically, in Q3 2020's revenue was $66.4M; in Q2 2020, it was $16.3M; in Q1 2020, it was $4.7M; in Q4 2019, Translate Bio's revenue was $3.9M.

Acquisitions

No recent acquisitions found related to Translate Bio

Translate Bio Funding History

$51M$172.6M$220.1M

Since Translate Bio was founded in 2016, it has participated in 3 rounds of funding. In total Translate Bio has raised $220.1M. Translate Bio's last funding round was on May 2019 for a total of $47.5M

ROUND

FUNDING DATE

AMOUNT

INVESTORS

Private Placement
May 2019
$47.5M
-
IPO
Jun 2018
$121.6M

Equity
Dec 2016
$51M
-

Since Translate Bio was founded in 2016, it has participated in 3 rounds of funding. In total Translate Bio has raised $220.1M. Translate Bio's last funding round was on May 2019 for a total of $47.5M

Investments

COMPANY

DESCRIPTION

AMOUNT

INVESTMENT DATE

ROUND

EXIT DATE

Chimerix is a pharmaceutical company that researches and develops novel antivirals for immunodeficiency.
$34.9M
Jul 25, 2019
Equity
Apr 10, 2013

Translate Bio News

December 22, 2020Seeking Alpha

Translate Bio finance chief departs

November 11, 2020REBusinessOnline

Translate Bio Signs 138,000 SF Life Sciences Lease in Metro Boston

WALTHAM, MASS. - Translate Bio, an RNA therapeutics company, has signed a 10-year, 138,000-square-foo... See more »
November 10, 2020The Business Journals: Boston

Biotech working on Covid vaccine plans HQ move to Waltham

A Lexington-based startup that's working on a Covid-19 vaccine has signed a 10-year-lease for 138,000... See more »
October 21, 2020MarketScreener

2020 NACFC Oral Presentation

(marketscreener.com) Delivering CFTR mRNA: An Inhaled, Mutation-agnostic Approach to Treat CF Richard... See more »
October 17, 2020Pharmabiz

Sanofi and Translate Bio announces preclinical results from mRNAbased vaccine candidate against SARSCoV2, MRT5500

Sanofi Pasteur, the vaccines global business unit of Sanofi, and Translate Bio, a clinical─stage mess... See more »
October 16, 2020Pharmaceutical Business Review

Sanofi, Translate Bio mRNA Covid-19 vaccine candidate induced high antibody levels in preclinical studies

Preclinical evaluation of MRT5500, importantly, demonstrated a favorable immune response profile agai... See more »

Translate Bio Press Releases

June 24, 2020GlobalNewswire

Translate Bio Announces Proposed Public Offering of Common Stock

LEXINGTON, Mass., June 24, 2020 (GLOBE NEWSWIRE) -- Translate Bio, Inc. (Nasdaq: TBIO), a clinical-st... See more »
February 19, 2020GlobalNewswire

Translate Bio to Present at Upcoming Investor Conferences

LEXINGTON, Mass, Feb. 19, 2020 (GLOBE NEWSWIRE) -- Translate Bio (Nasdaq: TBIO), a clinical-stage mes... See more »
May 28, 2019GlobeNewswire

Translate Bio to Present at the Jefferies 2019 Healthcare Conference

LEXINGTON, Mass., May 28, 2019 (GLOBE NEWSWIRE) -- Translate Bio, Inc. (Nasdaq: TBIO), a clinical-sta... See more »
May 9, 2019GlobeNewswire

Translate Bio Announces First Quarter 2019 Financial Results and Provides Corporate Update

-- Completed dosing in single-ascending dose portion of Phase 1/2 clinical trial in cystic fibrosis; ... See more »
March 21, 2019GlobeNewswire

Translate Bio Announces Fourth Quarter and Full Year 2018 Financial Results and Reviews Recent Highlights

LEXINGTON, Mass., March 21, 2019 (GLOBE NEWSWIRE) -- Translate Bio (Nasdaq: TBIO), a clinical-stage m... See more »
February 14, 2019GlobeNewswire

Translate Bio to Present at the 8th Annual SVB Leerink Partners Global Healthcare Conference

LEXINGTON, Mass., Feb. 14, 2019 (GLOBE NEWSWIRE) -- Translate Bio (Nasdaq: TBIO), a clinical-stage me... See more »
November 9, 2018Central Charts

Translate Bio Announces Third Quarter 2018 Financial Results and Reviews Recent Highlights

Translate Bio (Nasdaq: TBIO), a clinical-stage messenger RNA (mRNA) therapeutics company developing a... See more »

Social Media

Headquarters

29 Hartwell Ave

Lexington, Massachusetts02421

1-617-945-7361

Driving Directions »

Trending Companies

Summary

ABOUT

Overview

Translate Bio researches, develops and commercializes mRNA therapeutics to treat gene dysfunction diseases. Translate Bio was founded in 2016. Translate Bio's headquarters is located in Lexington, Massachusetts, USA 02421. It has raised 220.1M in 3 ro...

CEO

Translate Bio's CEO, Ronald C. Renaud, currently has an approval rating of 82%. Translate Bio's primary competitors are NexImmune, Checkmate Pharmaceuticals & Repare Therapeutics Inc..

Website

translate.bio

Frequently Asked Questions about Translate Bio

  1. When was Translate Bio founded?

    Translate Bio was founded in 2016
  2. Who is Translate Bio's CEO?

    Translate Bio's CEO is Ronald C. Renaud
  3. How much revenue does Translate Bio generate?

    Translate Bio generates $91.3M in revenue
  4. How much funding does Translate Bio have?

    Translate Bio has historically raised $220.1M in funding
  5. Where is Translate Bio's headquarters?

    Translate Bio's headquarters is in Lexington Massachusetts, USA
  1. How many employees does Translate Bio have?

    Translate Bio has 81 employees
  2. What sector does Translate Bio operate in?

    Translate Bio is in Biotechnology
  3. Who are Translate Bio's competitors?

    Translate Bio's top competitors are NexImmune, Checkmate Pharmaceuticals, Repare Therapeutics Inc.
  4. Who has Translate Bio invested in?

    Translate Bio's has invested in companies such as Chimerix